Group 1: Company Overview - Shanghai Laishi Blood Products Co., Ltd. is a leading enterprise in the domestic blood products industry, with a comprehensive product range and high plasma utilization rate [2][3]. - The company has four production bases located in Shanghai, Zhengzhou, Hefei, and Wenzhou, and operates 42 plasma collection stations across 11 provinces [3][4]. Group 2: Share Buyback Plan - The company plans to repurchase shares with a total fund amount of no less than RMB 500 million and not exceeding RMB 1 billion, with a repurchase price not exceeding RMB 8.00 per share [3][4]. - Of the repurchased shares, 30% will be used for cancellation to reduce registered capital, while 70% will be used for employee stock ownership plans [3]. Group 3: Future Development and Production Trends - The company aims to enhance plasma collection through better management of existing stations and the establishment of new ones, with annual collection volume disclosed in future reports [3][4]. - Zhengzhou Laishi, which resumed production in December 2021, is expected to stabilize its capacity, yield, sales revenue, and profit margins within 2-3 years [4][5]. Group 4: Financial Performance and Dividends - In June 2023, the company announced a cash dividend of RMB 0.30 per share, based on a total share capital of 6,740,787,907 shares [3][4]. - The company reported a 17% year-on-year increase in plasma collection volume in 2022, with stable production and sales of existing products [4][5]. Group 5: Strategic Partnerships - The company has a strategic cooperation agreement with GDS, focusing on quality management, technology research and development, and sales channels, which positively impacts its operations [4][5]. - GDS has achieved a cumulative EBITDA of USD 1.141 billion from 2019 to 2022, with an average annual EBITDA of USD 285 million [5].

证券代码：002252 证券简称：上海莱士 上海莱士血液制品股份有限公司 投资者关系活动记录表 | --- | --- | |--------------------|---------------| | | √特定对象调研 | | 投资者关系活动类别 | □媒体采访 □ | | | □新闻发布会 □ | | | □现场参观 | 长城证券股份有限公司 李华云 浦银安盛基金管理有限公司 徐博 西部证券股份有限公司 李梦园、徐子悦 OrbiMed Healthcare Fund Management 胡昱青、星璇 海通证券股份有限公司 郑琴、李恒宇、彭娉 富国基金管理有限公司 王园园 兴全基金管理有限公司 谢长雁 长江养老保险股份有限公司 戴颖 参与单位名称 及人员姓名 淳厚基金管理有限公司 严安定 兴业证券经济与金融研究院 姚晟瑜 中信保诚基金管理有限公司 陈爽 申万菱信基金管理有限公司 强泽平 中信证券股份有限公司 王凯旋、王郑洋 农银汇理基金管理有限公司 李蕾 上海冲积资产管理中心(有限合伙) 张智聪 上海鹤禧投资管理有限公司 吴迪龙 华泰柏瑞基金管理有限公司 邹丽晴 上海朴石投资管理合伙企业（有限合伙） ...

Group 1: Company Overview - Shanghai Laishi Blood Products Co., Ltd. is a leading enterprise in the blood products industry in China [2] - The company has four production entities and also acts as an agent for imported human albumin products, enhancing market competitiveness [4] Group 2: Plasma Collection and Product Trends - The annual plasma collection growth in the blood products industry is approximately 8%-10% [2] - The company aims to increase the utilization rate of raw plasma in coagulation factor products and expand its market share in this category [3] Group 3: Financial Performance and Profitability - The gross margin for the company's coagulation factor products is approximately 85% as reported in the 2022 annual report [4] - The gross margin for imported human albumin products is around 25%, with pricing largely consistent across different brands in the market [4] Group 4: Shareholding and Corporate Governance - The largest shareholder, Jilifu, holds 26.20% of the company's shares and has nominated five non-independent director candidates [3] - The company currently has no controlling shareholder or actual controller, which may change depending on the outcome of the upcoming shareholder meeting [3]

证券代码：002252 证券简称：上海莱士 上海莱士血液制品股份有限公司 投资者关系活动记录表 | --- | --- | |--------------------|---------------| | | √特定对象调研 | | 投资者关系活动类别 | □媒体采访 □ | | | □新闻发布会 □ | | | □现场参观 | 西南证券股份有限公司 杜向阳、王彦迪、汪艺 广发基金管理有限公司 王蓄锐 华安基金管理有限公司 桑翔宇 汇添富基金管理股份有限公司 谢杰 富国基金管理有限公司 娄圣睿 交银施罗德基金管理有限公司 徐嘉辰 天弘基金管理有限公司 王政眸 上海高毅资产管理合伙企业（有限合伙） 刘慧敏 财通基金管理有限公司 戚梦嘉 参与单位名称 及人员姓名 太平养老保险股份有限公司 张翼 上海睿扬投资管理有限公司 王世超 太平基金管理有限公司 闫庚威、陆玲玲 鹏扬基金管理有限公司 崔洁铭、王雪刚 国联安基金管理有限公司 赵子淇 泰信基金管理有限公司 刘名超 兴业基金管理有限公司 裘若桑 中国银河证券股份有限公司 程培 上海星河数码投资有限公司 谭玲、施彦礼、金铖 永安国富资产管理有限公司 李勇 上海混沌淡然 ...

证券代码： 002252 证券简称：上海莱士 上海莱士血液制品股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------------------|------------| | | | 2023-001 | | 投资者关系活动 | □ 分析师会议 | | | 类别 | 业绩说明会 | | | | 路演活动 | | | | | | | | （请文字说明其他活动内容） | | | 参与单位名称及 | | | | 人员姓名 | | | | 时间 | 周一) 下午 15:00~17:00 | | | 地点 | 公司通过全景网"投资者关系互动平台"（ | ）采用网络 | | | | | | 上市公司接待人 | Jun Xu（徐俊）先生 | | | 员姓名 | | | | | | | 4、独立董事：彭玲女士 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： 1、不能否认这么多年大股东被动减持对股价的压制，贵公司是否考虑通 过回购股票已对冲此部分影响，很多股民陪跑多年 您好！感谢您对我公司 ...

Financial Performance - The company's revenue for Q1 2023 was ¥2,063,038,679.08, representing a 22.40% increase compared to ¥1,685,498,423.72 in the same period last year[3] - Net profit attributable to shareholders was ¥718,568,079.44, up 31.12% from ¥548,033,363.89 year-on-year[3] - Basic earnings per share rose to ¥0.107, reflecting a 32.10% increase from ¥0.081 in the same quarter last year[3] - Total operating revenue for the current period reached ¥2,063,038,679.08, a 22.4% increase from ¥1,685,498,423.72 in the previous period[16] - Net profit for the current period was ¥718,266,042.76, representing a 31.4% increase compared to ¥545,987,550.05 in the previous period[17] - Operating profit rose to ¥842,272,279.67, an increase of 30.5% from ¥645,693,141.36 in the previous period[17] - The company reported a total comprehensive income of ¥528,071,210.89, compared to ¥479,205,487.47 in the previous period[17] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥1,070,515,512.59, a significant increase of 157.77% compared to ¥415,302,906.87 in the previous year[3] - Cash flow from operating activities generated a net amount of ¥1,070,515,512.59, significantly up from ¥415,302,906.87 in the previous period[20] - Cash and cash equivalents at the end of the period totaled ¥3,631,414,859.74, compared to ¥2,660,030,335.64 at the end of the previous period[21] - The company's cash and cash equivalents increased to RMB 4,569,595,868.99 from RMB 3,977,425,328.72, representing a growth of about 14.8%[11] - The company reported a significant increase in cash reserves, which may support future investments and operational expansions[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥31,008,256,414.76, a 1.81% increase from ¥30,457,959,495.12 at the end of the previous year[3] - The total liabilities of the company as of March 31, 2023, were RMB 1,666,806,771.14, slightly up from RMB 1,644,618,113.59 at the beginning of the year[13] - The equity attributable to shareholders of the parent company increased to RMB 29,347,122,761.37 from RMB 28,818,712,462.60, reflecting a growth of approximately 1.8%[13] - The company's non-current assets totaled RMB 22,354,391,292.06, up from RMB 21,984,549,673.90, indicating an increase of about 1.7%[12] Research and Development - The company's R&D expenses increased by 33.77% to ¥46,017,682.81, driven by an expansion in research activities[6] - Research and development expenses increased to ¥46,017,682.81, up from ¥34,400,140.41 in the previous period, indicating a focus on innovation[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 123,870, with the largest shareholder holding 26.20% of the shares[8] Other Financial Metrics - The weighted average return on equity improved to 2.47%, up 0.37 percentage points from 2.10% in the previous year[3] - The company experienced a 99.61% decrease in other current assets, primarily due to a reduction in deductible VAT input tax[6] - Accounts receivable decreased to RMB 523,036,139.16 from RMB 707,021,384.74, indicating a decline of approximately 26%[11] - Inventory levels decreased to RMB 3,064,179,372.22 from RMB 3,268,843,130.57, showing a reduction of about 6.3%[12] - The company reported a significant increase in government subsidies, totaling ¥2,427,675.03, although this was a 39.82% decrease compared to the previous year[7] - The company's short-term borrowings and other financial liabilities were not detailed in the provided data, indicating a focus on operational liquidity management[13] - The overall financial health of the company appears stable, with a solid increase in total assets and equity, despite some declines in receivables and inventory levels[14]

Financial Performance - The company's operating revenue for 2022 was ¥6,567,198,581.04, representing a 53.16% increase compared to ¥4,287,726,749.67 in 2021[11]. - The net profit attributable to shareholders for 2022 was ¥1,880,090,066.90, up 45.24% from ¥1,294,510,050.46 in 2021[11]. - The net profit after deducting non-recurring gains and losses was ¥1,826,062,740.20, a 33.40% increase from ¥1,368,820,159.04 in 2021[11]. - The net cash flow from operating activities for 2022 was ¥1,725,596,063.70, reflecting a 33.35% increase compared to ¥1,294,013,219.19 in 2021[11]. - The total assets at the end of 2022 were ¥30,457,959,495.12, an 11.83% increase from ¥27,236,582,048.82 at the end of 2021[11]. - The net assets attributable to shareholders at the end of 2022 were ¥28,818,712,462.60, up 11.26% from ¥25,902,445,517.58 at the end of 2021[11]. - The company reported a weighted average return on equity of 6.87% for 2022, an increase of 1.79 percentage points from 5.08% in 2021[11]. - The company's total revenue for 2022 reached ¥6,567,198,581.04, representing a 53.16% increase compared to ¥4,287,726,749.67 in 2021[41]. - The blood product segment generated ¥6,504,836,891.84, accounting for 99.05% of total revenue, with a year-on-year growth of 51.81%[41]. - The company reported a total operating cost of approximately CNY 3.67 billion, a 77.56% increase from the previous year[45]. Dividend Distribution - The company plans to distribute a cash dividend of 0.30 RMB per 10 shares to all shareholders, with no bonus shares or capital increase from reserves[2]. - The total cash dividend for the year 2022 was RMB 202,223,637.21, which is inclusive of all distribution methods[139]. - The company has no plans for stock dividends or capital reserve transfers in the current profit distribution[139]. - The company’s cash dividend policy complies with relevant laws and regulations, ensuring protection for minority shareholders[138]. Market Position and Growth - The blood product industry is experiencing steady growth due to increased clinical application and market demand, despite external pressures[15]. - The company is a leading player in China's blood products industry, with a comprehensive product range and high plasma utilization rate[22]. - The company has seen a notable increase in market share through collaboration with key opinion leaders in various medical fields, enhancing its brand image and industry leadership[24]. - The company is positioned to benefit from the increasing concentration in the blood products industry, with major players dominating the market[21]. - The company has achieved a record plasma collection volume of over 1,400 tons during the reporting period, marking a historical high[33]. - The company operates 42 plasma collection stations across 11 provinces, ranking among the top in the industry for both station count and plasma collection volume[23]. Research and Development - The company is actively pursuing research and development in hemophilia treatment and exploring new clinical indications for its products[34]. - The company is in the pre-clinical development stage for several new products, including a 10% intravenous immunoglobulin and an activated prothrombin complex, aimed at enhancing product lines and competitiveness[54]. - The company plans to continue its commitment to research and development to drive innovation in blood product solutions[100]. - The company is investing CNY 500 million in R&D for new blood product technologies over the next three years[148]. Operational Efficiency and Management - The company has strengthened its management and operational strategies to enhance plasma source expansion, focusing on both existing and new plasma collection stations[32]. - The company has implemented a comprehensive quality management system, ensuring the safety, quality, and efficiency of its products[35]. - The company has enhanced its internal management efficiency and operational levels, focusing on a high-standard quality management system[38]. - The company aims to optimize resource allocation and improve cost control in its plasma station operations[83]. - The company is focused on expanding its plasma source and improving operational management capabilities[83]. Risks and Challenges - The company faces risks including raw material supply, rising plasma costs, potential product safety issues, and goodwill impairment[2]. - The supply-demand imbalance for raw plasma remains significant, with the number of single plasma collection stations in China being insufficient to meet actual demand[16]. - The company is exposed to currency exchange risks due to its import trade primarily settled in USD and plans to monitor foreign currency transactions to mitigate this risk[91]. Corporate Governance - The company has established a complete and clear internal governance structure, complying with relevant laws and regulations[93]. - The company is committed to enhancing its corporate governance structure by filling independent director positions as required by regulations[101]. - The company continues to strengthen its internal control system to improve governance levels[93]. - The company has made revisions to its governance documents, including the company charter and shareholder meeting rules, to improve operational efficiency[126]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[146]. - The company has implemented measures to ensure compliance with environmental standards and regulations[146]. - The wastewater treatment facility operates with a process including regulation, acid hydrolysis, and disinfection, ensuring effective pollutant removal[163]. - The company has received multiple environmental approvals for its projects, including a recent wastewater discharge permit valid until December 2023[159]. Strategic Partnerships and Acquisitions - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product portfolio[100]. - The company has completed two strategic acquisitions in 2022, enhancing its production capacity by 30%[150]. - The company has established exclusive distribution rights for Grifols, S.A. products in China, excluding Hong Kong, Macau, and Taiwan[192]. Employee Management and Welfare - The total number of employees at the end of the reporting period was 3,121, with 618 in the parent company and 2,503 in major subsidiaries[131]. - The company provided additional benefits such as paid leave, annual health checks, and supplementary medical insurance to enhance employee welfare[133]. - The company implemented a performance-based salary adjustment and bonus distribution policy to align organizational goals with individual objectives[133].

2、召开方式：网络远程的方式 3、出席人员：公司董事、总经理徐俊先生，独立董事彭玲女士，副总经理、 董事会秘书刘峥先生、财务负责人陈乐奇先生等。 证券代码：002252 证券简称：上海莱士 公告编号：2023-022 上海莱士血液制品股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）已于2023年4月25日在巨潮资讯 网上披露了《2022年年度报告》等。为便于广大投资者更加全面深入地了解公司 生产经营等情况，公司定于2023年5月8日（星期一）15:00-17:00在全景网举办2022 年度网上业绩说明会，与投资者进行沟通和交流，听取投资者的意见和建议。本 次网上说明会的具体情况如下： 一、 本次业绩说明会安排 1、召开时间：2023年5月8日（星期一）15:00-17:00 （问题征集专题页面二维码） 欢迎广大投资者积极参与本次网上说明会。 特此公告。 上海莱士血液制品股份有限公司 董事会 4、投资者参与方式：投资者可登录全景网"投资者关系互动平台" （https: ...

Group 1: Company Structure and Shareholding - The major shareholder after the restructuring is Jilifu, holding 26.2% of the company [2] - The controlling shareholders remain Keri Tiancheng and Laisi China [2] - The restructuring involved the transfer of 45% GDS shares to the company [2][4] Group 2: Debt Management and Financial Strategy - The controlling shareholder is managing debt through communication with creditors and extending debt terms [3] - There is no active reduction of company shares by the controlling shareholder, with some passive reductions due to creditor actions [3] Group 3: Value Enhancement from Restructuring - The restructuring is expected to optimize the industry structure by expanding into the in-vitro diagnostics field [3] - The introduction of advanced management practices from Jilifu is anticipated to improve operational efficiency and profitability [3] - Collaboration with Jilifu will enhance production quality, technology development, and market presence [3] Group 4: GDS Business Performance - GDS is a leading global manufacturer of blood testing instruments and reagents, with a strong market share in nucleic acid testing [4] - GDS has expanded its product line, including new testing reagents for Zika virus and Babesia [4] - The acquisition of GDS shares is expected to positively impact the company's financial performance [4] Group 5: Plasma Collection and Industry Trends - The company operates 41 plasma collection stations across 11 provinces [5] - The pandemic has temporarily affected plasma collection, but operations have resumed [5] - The blood products industry is expected to maintain stable growth despite challenges from the pandemic [5] Group 6: Sales and Marketing Strategy - The company has shifted to a dual sales model, combining commercial channels with hospital sales [5] - Various marketing strategies are being employed to maximize business growth opportunities [5] - The blood products industry remains robust, with significant potential for clinical application [5]